Exec. Vice Chairman/CEO/Pres. of Hemispherx Biopharma Inc (HEB, Financial) Thomas K. Equels bought 29,404 shares of HEB on 06/21/2019 at an average price of $4.03 a share. The total cost of this purchase was $118,498.
Hemispherx Biopharma Inc is a specialty pharmaceutical company. It is primarily engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. Hemispherx Biopharma Inc has a market cap of $9.260 million; its shares were traded at around $4.21 with and P/S ratio of 14.72. Hemispherx Biopharma Inc had annual average EBITDA growth of 18.80% over the past ten years.
CEO Recent Trades:
- Exec. Vice Chairman/CEO/Pres. Thomas K. Equels bought 29,404 shares of HEB stock on 06/21/2019 at the average price of $4.03. The price of the stock has increased by 4.47% since.
- Exec. Vice Chairman/CEO/Pres. Thomas K. Equels bought 29,404 shares of HEB stock on 06/21/2019 at the average price of $4.03. The price of the stock has increased by 4.47% since.
Directors and Officers Recent Trades:
- Sr. VP of Operations Wayne S Springate bought 5,211 shares of HEB stock on 06/21/2019 at the average price of $4.03. The price of the stock has increased by 4.47% since.
- Director William M Mitchell bought 9,677 shares of HEB stock on 06/21/2019 at the average price of $4.03. The price of the stock has increased by 4.47% since.
- Director Stewart Appelrouth bought 9,677 shares of HEB stock on 06/21/2019 at the average price of $4.03. The price of the stock has increased by 4.47% since.
- Chief Science/Medical Officer David R Strayer bought 2,481 shares of HEB stock on 06/21/2019 at the average price of $4.03. The price of the stock has increased by 4.47% since.
- Dir Govt Relations/Sectry Iii Peter W. Rodino bought 8,695 shares of HEB stock on 06/21/2019 at the average price of $4.03. The price of the stock has increased by 4.47% since.
For the complete insider trading history of HEB, click here
.
